Therapeutic effect of recombinant human interferon α1b combined with Yanhuning on children with hand,foot,and mouth disease
Objective:To analyze the effect of recombinant human interferon α1b for injection combined with Yanhuning in the treatment of pediatric hand,foot,and mouth disease.Methods:Sixty children with HFMD treated in our hospital from January 2020 to December 2022 were randomly divided into a control group(n=30)and a study group(n=30).The control group was treated with an intravenous injection of ribavirin injection 15 mg·kg-1.Based on this,the study group was treated with intramuscular injection of recombinant human interferon α1b 1 μg·kg-1 and intravenous injection of Yanhuning injection 10 mg·kg-1.After 5 days of treatment,tumor necrosis factorα-α(TNF-α)and interleukin-6(IL-6)were determined by double-antibody sandwich enzyme-linked immunosorbent assay(ELISA),and C-reaction protein(CRP)was determined by scattering turbidimetry.The recovery,clinical efficacy,and adverse reactions of the two groups were compared.Results:The duration of fever,oral ulcer,hand and foot rash and hospital stay in the study group were significantly shorter than those in the control group(P<0.05).The total effective rate of treatment was significantly higher than that of the control group(P<0.05).After treatment,the levels of CRP,TNF-α,and IL-6 in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:The combination of recombinant human interferon α1b and Yanhuning can relieve the symptoms of children,inhibit the inflammatory response,and accelerate recovery.
YanhuningHand,foot,and mouth diseaseRecombinant human interferonT lymphocyte subpopulationsInflammatory factors
NETL
NSTL
万方数据
维普
